Zobrazeno 1 - 10
of 186
pro vyhledávání: ''
Autor:
Toshiyuki Takehara, Kimio Yonesaka, Hitomi Sakai, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Hisato Kawakami, Kazuhiko Nakagawa, Takeshi Teramura, Shinichiro Suzuki, Kazuto Nishio, Ryoji Kato, Junko Tanizaki
Publikováno v:
Clinical Cancer Research. 27:5697-5707
Purpose: Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhi
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Ruihua Bai, Tianshun Zhang, Yongping Song, Qingxin Xia, Kangdong Liu, Zigang Dong, Qiushi Wang, Xiang Li, Keke Wang, Xiaoyu Chang, Ting Wang, Ann M. Bode, Joohyun Ryu, Wei-Ya Ma
Publikováno v:
Cancer Prevention Research. 12:837-848
Lung cancer is the leading cause of cancer-related death worldwide. However, promising agents for lung cancer prevention are still very limited. Identification of preventive targets and novel effective preventive agents is urgently needed for clinica
Autor:
Thomas Roeder, Lia Burkhardt, Judith Bossen, Line Steen, Iris Bruchhaus, Karin Uliczka, Christine Fink, Mandy Mong-Quyen Mai, Roxana Pfefferkorn, Michael Spohn, Holger Heine
Publikováno v:
Molecular Cancer Therapeutics. 18:1659-1668
Lung cancer is the leading cause of cancer-associated mortality. Mutations in the EGFR gene are among the most important inducers of lung tumor development, but success of personalized therapies is still limited because of toxicity or developing resi
Autor:
Carmen Maria Barnes, Ellen Filvaroff, Shi Tao, Mehnaz Malek, Gordon L. Bray, Winfried Elis, Yumin Dai, Konstantinos Mavrommatis, Lixin Qiao, Terri Jones, Ida Aronchik, Beebe Lisa, Matt Labenski
Publikováno v:
Molecular Cancer Research. 17:642-654
As a critical signaling node, ERK1/2 are attractive drug targets, particularly in tumors driven by activation of the MAPK pathway. Utility of targeting the MAPK pathway has been demonstrated by clinical responses to inhibitors of MEK1/2 or RAF kinase
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Gregory J. Riely, Marc Ladanyi, Ryan Kim, Ken Suzawa, Matthew D. Hellmann, Helena A. Yu, Maria E. Arcila, Ahmet Zehir, Ai Ni, Bob T. Li, Michael F. Berger, Romel Somwar, Emmet Jordan, Mark G. Kris, David B. Solit
Publikováno v:
Clinical Cancer Research. 24:3108-3118
Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled EGFR-mutant tumors prior to treatment and after progression on
Autor:
Jill Hallin, Lyudmilla Bazhenova, James G. Christensen, Natalia Baños, Richard C. Chao, Camino Menéndez, Mark M. Awad, Nir Peled, Mizuki Nishino, Peter Olson, V. Tassell, Richard B. Lanman, Geoffrey I. Shapiro, Matthew Randolf Lee, Lars D. Engstrom, Zachary Madaj, Sandip Pravin Patel, Manuel Hidalgo, Ruth Aranda, Carrie R. Graveel, Pasi A. Jänne, David Briere, Elizabeth A. Tovar, Curt J. Essenburg, Harrah Chiang, Pedro P. López-Casas, Darya Chudova
Publikováno v:
Clinical Cancer Research. 23:6661-6672
Purpose: MET exon 14 deletion (METex14 del) mutations represent a novel class of non–small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a spectrum-selective MET inhibitor exhibiting a type II binding mode, in METex14 del–po
Autor:
Max M. Quinn, Xiaoen Wang, Cyril H. Benes, Ashley A. Merlino, Qingsong Liu, Yuyang Li, Peng Gao, Kwok-Kin Wong, Nathanael S. Gray, Feiyang Liu, Fei Li, Yan Liu
Publikováno v:
Cancer Research. 77:5068-5076
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/